Literature DB >> 15177541

Management of refractory inflammatory bowel disease.

Craig A Solem1, Edward V Loftus.   

Abstract

One of the most challenging aspects of the management of inflammatory bowel disease is the high frequency of incomplete or absent response to medical therapy. Although many patients may be truly refractory to medical therapy, a lack of response may indicate several possibilities, including incorrect diagnosis, progression of disease extent, intestinal complication, superinfection, underdosing of therapy, monotherapy instead of combination therapy, or medication intolerance. This article provides a practical general approach to refractory inflammatory bowel disease patients encountered in clinical practice.

Entities:  

Mesh:

Year:  2004        PMID: 15177541     DOI: 10.1016/j.gtc.2004.02.011

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  1 in total

1.  Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease.

Authors:  Basil S Nasir; Eric J Dozois; Robert R Cima; John H Pemberton; Bruce G Wolff; William J Sandborn; Edward V Loftus; David W Larson
Journal:  J Gastrointest Surg       Date:  2010-09-25       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.